The National Institute of Health COVID-19 treatment guidelines recommend against the use of immunomodulators for the treatment of COVID-19, except in a clinical trial. 
Among patients who have been admitted to the hospital with COVID-19, the Infectious Diseases Society of America guideline panel suggests against the routine use of tocilizumab. 
A review article assessing tocilizumab in COVID-19 acute respiratory distress syndrome (ARDS) found that one- or two-times administration of intravenous and subcutaneous tocilizumab may be considered to be safe in patients with severe COVID-19. Researchers concluded that given the limited data, further randomized trials needed to take place to confirm the role of tocilizumab in COVID-19. 
A review article assessing potential therapeutic targets in COVID-19 stated that tocilizumab may be effective in the cytokine storm phase of COVID-19. 
A review article assessing current therapeutic agents for COVID-19 stated that tocilizumab may be used as adjunct therapy to blunt the cytokine storm seen in progressing COVID-19 disease. 
A review article assessing the cytokine storm seen in COVID-19 stated that clinical data showed improved hypoxgenmia, CT opacity, and symptoms after treatment with tocilizumab, suggesting that tocilizumab could be an efficient therapeutic agent for treatment of the cytokine storm associated with COVID-19. 
A meta-analysis assessing the efficacy of tocilizumab for the treatment of severe COVID-19 included studies comparing the clinical efficacy of tocilizumab and its competitors that explicitly reported at least all-cause mortality, intensive care unit (ICU) admission, and/or requirement for mechanical ventilation (MV). Researchers concluded that there is no suggestion that tocilizumab would provide any additional benefit for patients with severe COVID-19.